Roth Capital Thinks Stemline Therapeutics Inc’s Stock is Going to Recover

In a report released today, Jotin Marango from Roth Capital maintained a Buy rating on Stemline Therapeutics Inc (STML), with a price target of $33. The company’s shares closed on Friday at $10.99, close to its 52-week low of $10.

Marango said:

“We like today’s update from the Phase 1/2 study of Elzonris in CMML. Earlier this year after EHA, we had pointed to spleen reduction as a key indicator of clinical benefit, and supportive of eventual approvability. Today’s update reinforced this point further by showing us a patient bridged to transplant, which we view as a big deal.”

According to, Marango has 0 stars on 0-5 star ranking scale with an average return of -9.4% and a 23.1% success rate. Marango covers the Healthcare sector, focusing on stocks such as KalVista Pharmaceuticals Inc, Cyclacel Pharmaceuticals, and Actinium Pharmaceuticals.

Currently, the analyst consensus on Stemline Therapeutics Inc is a Strong Buy with an average price target of $30.33, which is a 176.0% upside from current levels. In a report issued on November 26, Piper Jaffray also initiated coverage with a Buy rating on the stock with a $20 price target.


See today’s analyst top recommended stocks >>

Based on Stemline Therapeutics Inc’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $21.04 million. In comparison, last year the company had a GAAP net loss of $16.06 million.

Based on the recent corporate insider activity of 26 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. Its clinical stage product candidates include SL-401, SL-801, and SL-701.

Read More on STML:

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts